These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 34589970)

  • 1. Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in
    Liao BC; Hsu WH; Lee JH; Yang CY; Tsai TH; Liao WY; Ho CC; Lin CC; Shih JY; Yu CJ; Soo RA; Yang JC
    JTO Clin Res Rep; 2021 Jan; 2(1):100099. PubMed ID: 34589970
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Buder A; Hochmair MJ; Setinek U; Pirker R; Filipits M
    Transl Lung Cancer Res; 2020 Apr; 9(2):239-245. PubMed ID: 32420063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study).
    Ang YLE; Zhao X; Reungwetwattana T; Cho BC; Liao BC; Yeung R; Loong HH; Kim DW; Yang JC; Lim SM; Ahn MJ; Lee SH; Suwatanapongched T; Kongchauy K; Ou Q; Yu R; Tai BC; Goh BC; Mok TSK; Soo RA
    Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation.
    Watanabe K; Saito R; Miyauchi E; Nagashima H; Nakamura A; Sugawara S; Tanaka N; Terasaki H; Fukuhara T; Maemondo M
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib.
    Romero A; Serna-Blasco R; Alfaro C; Sánchez-Herrero E; Barquín M; Turpin MC; Chico S; Sanz-Moreno S; Rodrigez-Festa A; Laza-Briviesca R; Cruz-Bermudez A; Calvo V; Royuela A; Provencio M
    Transl Lung Cancer Res; 2020 Jun; 9(3):532-540. PubMed ID: 32676317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAPP-seq analysis of circulating tumor DNA from patients with EGFR T790M-positive lung cancer after osimertinib.
    Kato R; Hayashi H; Sakai K; Suzuki S; Haratani K; Takahama T; Tanizaki J; Nonagase Y; Tanaka K; Yoshida T; Takeda M; Yonesaka K; Kaneda H; Nishio K; Nakagawa K
    Int J Clin Oncol; 2021 Sep; 26(9):1628-1639. PubMed ID: 34117553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
    Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
    Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib.
    Ding PN; Roberts TL; Chua W; Becker TM; Caixeiro N; de Souza P; Gao B; Lee CK; Itchins M; Westman H; Clarke S; Blinman P; Kao S; John T; Leal JL; Bray VJ
    Transl Lung Cancer Res; 2021 Apr; 10(4):1623-1634. PubMed ID: 34012779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-Free Tumor DNA (ctDNA) Utility in Detection of Original Sensitizing and Resistant EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC).
    Agulnik JS; Papadakis AI; Pepe C; Sakr L; Small D; Wang H; Kasymjanova G; Spatz A; Cohen V
    Curr Oncol; 2022 Feb; 29(2):1107-1116. PubMed ID: 35200593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome.
    Vendrell JA; Quantin X; Aussel A; Solassol I; Serre I; Solassol J
    Transl Lung Cancer Res; 2021 Nov; 10(11):4084-4094. PubMed ID: 35004240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance.
    Zheng D; Ye X; Zhang MZ; Sun Y; Wang JY; Ni J; Zhang HP; Zhang L; Luo J; Zhang J; Tang L; Su B; Chen G; Zhu G; Gu Y; Xu JF
    Sci Rep; 2016 Feb; 6():20913. PubMed ID: 26867973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA.
    Ikushima H; Sakatani T; Usui K
    Oncology; 2020; 98(1):23-28. PubMed ID: 31494653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osimertinib in NSCLC: Real-World Data From New Zealand.
    So YJ; Fraser A; Rivalland G; McKeage M; Sullivan R; Cameron L
    JTO Clin Res Rep; 2020 Jun; 1(2):100022. PubMed ID: 34589929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of genomic alternations in epidermal growth factor receptor (EGFR)-T790M-mutated non-small cell lung cancer (NSCLC) patients with acquired resistance to osimertinib therapy.
    Hsu PC; Chang JW; Chiu LC; Yang CT; Kuo SC; Fang YF; Wu CE
    Clin Transl Oncol; 2024 Sep; ():. PubMed ID: 39317868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of EGFR T790M detection by ddPCR and ARMS-PCR and the effect of mutant abundance on the efficacy of osimertinib in NSCLC patients.
    Li Y; Xu Y; Wu X; He C; Liu Q; Wang F
    J Thorac Dis; 2019 Jul; 11(7):3004-3014. PubMed ID: 31463130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer.
    Jenkins S; Yang JC; Ramalingam SS; Yu K; Patel S; Weston S; Hodge R; Cantarini M; Jänne PA; Mitsudomi T; Goss GD
    J Thorac Oncol; 2017 Jul; 12(7):1061-1070. PubMed ID: 28428148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring
    Chen CH; Chang JW; Chang CF; Huang CY; Yang CT; Kuo CS; Fang YF; Hsu PC; Wu CE
    Anticancer Res; 2022 Apr; 42(4):2145-2157. PubMed ID: 35347039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer.
    Pan G; Chen K; Yu X; Sheng J; Fan Y
    Transl Cancer Res; 2021 Jun; 10(6):2895-2905. PubMed ID: 35116599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (
    Xu Z; Hao X; Wang Q; Wang J; Yang K; Wang S; Teng F; Li J; Xing P
    Cancer Manag Res; 2022; 14():863-873. PubMed ID: 35256860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tag-based next generation sequencing: a feasible and reliable assay for EGFR T790M mutation detection in circulating tumor DNA of non small cell lung cancer patients.
    Dono M; De Luca G; Lastraioli S; Anselmi G; Dal Bello MG; Coco S; Vanni I; Grossi F; Vigani A; Genova C; Ferrarini M; Ravetti JL; Zupo S
    Mol Med; 2019 Apr; 25(1):15. PubMed ID: 31029076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.